Autopsy report · NCT02769494

The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer

“Lack of funds”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Xijing Hospital of Digestive Diseases

Sponsor type

University, hospital or other

Conditions

Crohn's Disease; Oral Ulcer

Interventions

Mesalazine Sustained-Release Tablets; Riboflavin Sodium Phosphate Injection

Participants

0

Sites

1

Countries

China

Trials that died the same way

• Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
  “lack of funding” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.